The relationship between the content of the potential psychopharmacological agent cyclo-L-prolylglycine in the brain of experimental animals and its antihypoxic effect
https://doi.org/10.37489/2587-7836-2020-1-25-29
Abstract
In the study of strutural and intracellular distribution of cyclo-t-prolylglycine (CPG) in brain rats in experiments on mongrel white male rats, it was found that CPG determined more in the hippocampus and cerebral cortex with predominant localization in the nuclear fraction of the rat brain, in the mitochondrial and microsomal fractions CPG is distributed approximately equivalently with a small quantitative predominance in the microsomal fraction. In an experimenlt using inbred mice of 2 lines: C57Black/6 and BALB/c, differing in behavior, opposite emotional response to stress, hypoxic influence. It was shown that the content CPG mice of the C57black/6 line are 39 % larger than in the brains of mice of the stress-unstable BALB/c line, which is probably due to differences in the manifestation of its it was shown that the content of CPG in the brain of stress-resistant mice C57Black/6 more than 39 % compared with the content of GPG in brain of mice BALB/c and the relationship between the quantitative content of CPG in the brain of these experimental animals and the manifestation of its antihypoxic effect was established.
About the Authors
V. P. Zherdev
FSBI Zakusov Institute of Pharmacology
Russian Federation
Russian Federation
Zherdev Vladimir - D,. Sci. in Medicine, professor, Head of laboratory pharmacokinetics, SPIN code: 2213-9592
Moscow
S. S. Boyko
FSBI Zakusov Institute of Pharmacology
Russian Federation
Russian Federation
Boyko Svetlana - PhD in Biology, Senior Research Officer of laboratory pharmacokinetics, SPIN code: 4176-8921.
Moscow
K. N. Kolyasnikova
FSBI Zakusov Institute of Pharmacology
Russian Federation
Russian Federation
Koliasnikova Ksenia - PhD in Biology, Research scientist of laboratory of peptide bioregulators of the Department of drug chemistry, SPIN code: 5682-2035.
Moscow
References
1. Boyko SS, Zherdev VP, Gudasheva ТА, Ostrovskaya RU, еt al. Pharmacokinetics of dipeptide analog pyracetame wich nootropic activity GWS-111 and its main metabolites. Experimental and Clinical Pharmacology. 1997;72(2):3—6. (In Russ).
2. Boyko SS, Zherdev VP, Gudasheva ТА, еt al. Pharmacokinetics of new potencial dipeptide nootrope GWS-111 and its main metabolites in rat brain. Khimico-Farmatsevicheskii Zhurnal. 2001;35(9):11—13. (In Russ).D0I:10.1023/AA10140824082406443
3. Gudasheva ТА, Boyko SS, Akparov VKh, еt al. Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. FEBS Leters. 1996; 391(1-2):149—152. DOI 10.1016/0014-5793(9600722-311.
4. Gudasheva ТA, Boyko SS, Ostrovskaya RU, еt al. The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and similarlity to endogenous neuropeptide cyclo-prolylglycine. Europ. J. Drug Metabol. and Pharmacokin. 1997;22(3):245—252. DOI: 1007/BF03189814
5. Gudasheva ТА, Ostrovskaya RU, Trofimov SS, et al. New endogenous dipetide cycloprolyl-glicine is similar to piracetam by its mnemotropic selectivity. Bulletin of experimental biology and medicine. 1999;128(10):411— 413. (In Russ).
6. Ostrovskaya RU, Gudasheva TA, Seredenin SB. The Novel Nootropic and Neuroprotector Drug Noopept (GVS-111) Experimental and Clinical Pharmacology. 2002;65(5):66-72. (In Russ). DOI: 10.30906/0869-2092-2002-65-5-66-7211
7. Kolyasnicova KN, Gudasheva TA, Nasarova GA, еt al. Similarity of cycloprolylglycine to piracetam in antigypoxic and neuroprotective effects. Experimental and Clinical Pharmacology. 2012;75(9):3-6. (In Russ).
8. Seredenin SB, Gudasheva TA, Boyko SS, Kovalyov GI, et al. Endogenous dipeptide cycloproliglicine shows selestivnuyu anksioliticescuyu activity in animals with a pronounced fear reaction. Bulletin of experimental biology and medicine. 2002;(4):417-419. (In Russ).
9. Boiko SS, Gudasheva TA, Zherdev VP, Seredenin SB. Regional and subcellular localization of cycloprolylglycine in the rat brain. Bulletin of experimental biology and medicine. 2010;149(6):648—650. (In Russ).
10. Ravalev GI, Zolotarev YuA, Dadayan AK, et al. The Study of Cycloprolylglycine Pharmacokinetics in Rat Blood. Farmakokinetika i farmakodinamika. 2018;(30):48— 54. (In Russ). DOI: 10.24411/2588-0519-2018-10024
11. Sudakov SK, Terebili-na NN, Medvedeva OF, et al. Changes in the content of substance P, peptide inhibiting the binding of diazepam, and neuropeptide Y in the brain of high-anxiety and low-anxiety inbred rats under stress. Bulletin of experimental biology and medicine. 1999; (9):254—257. (In Russ).
12. Prasad CH, Mori M, Pierson W, et al. Development changes in the distribution of rat brain pyroglutamate aminopeptidase, a possible determinant of endogenous cyclo (HIS-PRO) concentrations. Neurochemical Research. 1983;8(3):389—399.
13. Prasad CH. Bioactive Cyclic Dipeptides. Peptides. 1995;16(1):151—164. DOI: 10.1016/0196-9781(94)00017-Z.
14. Kondrakhin EA, Salimov RM, Nesnamov GG, Kovalev GI. Comparison of behavior and neuroreceptor effects of pantogam and bemiil with single and multiply injections in mice of C57BL/6 and Balb/c. Farmakokinetika ifarmakodinamika. 2015;(1):44—51. (In Russ).
15. Kovalev IG, Vasileva EV, Bokov RO, Kovalev GI. The effects of levetiracetam and a new 4-phenylpyrrolidone derivate GIZh-290 in a closed cross-maze in BALB/c and C57 Bl/6 mice. Farmakokinetika ifarmakodinamika. 2017;(2):25—29. (In Russ).
16. Vasileva EV, Salimov RM, Kovalev GI. Comparison of pharmacological effects of heptapeptide selank in intraperitoneale and intranasale injection. Farmakokinetika ifarmakodinamika. 2017;(3):3—6. (In Russ).
17. Guan J, Gluchman P, Yang P, et al. Cyclic glycine-prolline regulates IGF-1 homeostasis by altring the binding of IGFbR-3 to IGF-1. Sci. Rep. 2014;(4):4388. DOI: 10.1038/srep0488
Review
For citations:
Zherdev V.P., Boyko S.S., Kolyasnikova K.N. The relationship between the content of the potential psychopharmacological agent cyclo-L-prolylglycine in the brain of experimental animals and its antihypoxic effect. Pharmacokinetics and Pharmacodynamics. 2020;(1):25-29. (In Russ.) https://doi.org/10.37489/2587-7836-2020-1-25-29
Views:
701
Email this article 